SynCore BiotechnologyLtd Past Earnings Performance
Past criteria checks 0/6
SynCore BiotechnologyLtd has been growing earnings at an average annual rate of 52.8%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 21.9% per year.
How SynCore BiotechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:4192 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
28
-45
44
24
31 Dec 25
27
-46
44
25
30 Sep 25
26
-46
43
25
30 Jun 25
25
-53
43
26
31 Mar 25
24
-55
44
27
31 Dec 24
23
-54
42
28
30 Sep 24
23
0
42
-30
30 Jun 24
23
-15
42
-16
31 Mar 24
21
-28
41
-5
31 Dec 23
20
-38
42
4
30 Sep 23
19
-162
42
130
30 Jun 23
18
-163
42
127
31 Mar 23
16
-170
41
141
31 Dec 22
16
-189
43
157
30 Sep 22
14
-187
43
155
30 Jun 22
11
-375
43
348
31 Mar 22
9
-429
42
391
31 Dec 21
7
-459
39
423
30 Sep 21
10
-481
38
444
30 Jun 21
12
-364
38
325
31 Mar 21
13
-386
38
352
31 Dec 20
13
-399
39
363
30 Sep 20
10
-409
40
375
30 Jun 20
8
-417
41
385
31 Mar 20
9
-430
43
398
31 Dec 19
13
-409
45
380
30 Sep 19
13
-389
45
362
30 Jun 19
13
-359
47
329
31 Mar 19
12
-306
47
276
31 Dec 18
8
-294
48
258
30 Sep 18
8
-270
46
229
30 Jun 18
8
-253
44
216
31 Mar 18
8
-247
44
212
31 Dec 17
8
-258
40
224
30 Sep 17
8
-186
39
228
30 Jun 17
8
-177
39
219
31 Mar 17
7
-176
37
223
31 Dec 16
7
-162
38
208
30 Sep 16
7
-185
39
179
30 Jun 16
7
-201
44
190
31 Mar 16
16
-179
47
168
31 Dec 15
15
-182
48
170
30 Sep 15
15
-223
58
204
30 Jun 15
15
-223
63
196
Quality Earnings: 4192 is currently unprofitable.
Growing Profit Margin: 4192 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4192 is unprofitable, but has reduced losses over the past 5 years at a rate of 52.8% per year.
Accelerating Growth: Unable to compare 4192's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4192 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-5%).
Return on Equity
High ROE: 4192 has a negative Return on Equity (-19.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/29 11:30
End of Day Share Price
2026/05/29 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SynCore Biotechnology Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.